Vallon Pharmaceuticals, Inc. also files under GRI; those filings are included.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 18, 2025 | Kelly Leanne | Chief Financial Officer | Grant(A) | 43K | — | $0 |
| Sep 18, 2025 | Szekeres David Leslie | Director | Grant(A) | 40K | — | $0 |
| Sep 18, 2025 | Rongen Roelof | Director | Grant(A) | 24K | — | $0 |
| Sep 18, 2025 | Simpson Camilla V | Director | Grant(A) | 24K | — | $0 |
| Sep 18, 2025 | Baker David Charles | Director | Grant(A) | 24K | — | $0 |
| Sep 18, 2025 | Hertz Walter Marc | Chief Executive Officer, Director | Grant(A) | 103K | — | $0 |
| Sep 18, 2025 | Chaturvedi Vipin | Chief Scientific Officer | Grant(A) | 43K | — | $0 |
| Aug 26, 2025 | Hertz Walter Marc | Chief Executive Officer, Director | Grant(A) | 27K | — | $0 |
| Aug 26, 2025 | Kelly Leanne | Chief Financial Officer | Grant(A) | 12K | — | $0 |
| Aug 26, 2025 | Simpson Camilla V | Director | Grant(A) | 6K | — | $0 |
| Aug 26, 2025 | Chaturvedi Vipin | Chief Scientific Officer | Grant(A) | 12K | — | $0 |
| Aug 26, 2025 | Rongen Roelof | Director | Grant(A) | 6K | — | $0 |
| Aug 26, 2025 | Baker David Charles | Director | Grant(A) | 6K | — | $0 |
| Aug 26, 2025 | Szekeres David Leslie | Director | Grant(A) | 10K | — | $0 |
| Aug 13, 2025 | Simpson Camilla V | Director | Grant(A) | 5K | — | $0 |
| Aug 13, 2025 | Szekeres David Leslie | Director | Grant(A) | 8K | — | $0 |
| Aug 13, 2025 | Rongen Roelof | Director | Grant(A) | 5K | — | $0 |
| Aug 13, 2025 | Baker David Charles | Director | Grant(A) | 5K | — | $0 |
| Jan 23, 2025 | Rongen Roelof | Director | Grant(A) | 30K | $0.69 | $21K |
| Jan 23, 2025 | Szekeres David Leslie | Director | Grant(A) | 52K | $0.69 | $36K |
| Jan 23, 2025 | Baker David Charles | Director | Grant(A) | 30K | $0.69 | $21K |
| Jan 23, 2025 | Simpson Camilla V | Director | Grant(A) | 30K | $0.69 | $21K |
| Jan 23, 2025 | Hertz Walter Marc | Chief Executive Officer, Director | Grant(A) | 130K | $0.69 | $90K |
| Jan 23, 2025 | Chaturvedi Vipin | Chief Scientific Officer | Grant(A) | 43K | $0.69 | $30K |
| Jan 23, 2025 | Kelly Leanne | Chief Financial Officer | Grant(A) | 43K | $0.69 | $30K |
| Sep 22, 2023 | Kelly Leanne | Chief Financial Officer | Grant(A) | 83K | $1.52 | $127K |
| Aug 10, 2023 | Baker David Charles | Director | Grant(A) | 34K | $2.90 | $100K |
| Aug 10, 2023 | Rongen Roelof | Director | Grant(A) | 34K | $2.90 | $100K |
| Aug 10, 2023 | Simpson Camilla V | Director | Grant(A) | 34K | $2.90 | $100K |
| Aug 10, 2023 | Szekeres David Leslie | Director | Grant(A) | 34K | $2.90 | $100K |
| Apr 21, 2023 | Chaturvedi Vipin | Chief Scientific Officer | Grant(A) | 172K | — | — |
| Apr 21, 2023 | Agro Albert | Chief Medical Officer | Grant(A) | 172K | — | — |
| Apr 21, 2023 | Hertz Walter Marc | Chief Executive Officer, Director, 10% Owner | Grant(A) | 386K | — | — |
| Dec 13, 2022 | Thorell Marella | Director | Other(J) | 29K | — | $0 |
| Jul 1, 2022 | Thorell Marella | Director | Grant(A) | 38K | — | $0 |
| Jun 9, 2022 | Payne Joseph E | Director | Grant(A) | 8K | — | $0 |
| Jun 9, 2022 | Thorell Marella | Director | Grant(A) | 8K | — | $0 |
| Jun 9, 2022 | Ammer Richard | Director | Grant(A) | 8K | — | $0 |
| Feb 23, 2022 | Chhabra Meenu | Director | Grant(A) | 15K | $7.67 | $115K |
| Feb 15, 2022 | Kelly Leanne M. | Chief Financial Officer | Grant(A) | 50K | $5.63 | $282K |
| Feb 15, 2022 | Baker David Charles | Chief Executive Officer, Director | Grant(A) | 61K | $5.63 | $343K |
| Jun 4, 2021 | Kelly Leanne M. | Chief Financial Officer | Buy(P) | 2K | $4.08 | $6K |
| Jun 3, 2021 | Kelly Leanne M. | Chief Financial Officer | Buy(P) | 1K | $4.05 | $4K |
| Jun 2, 2021 | Kelly Leanne M. | Chief Financial Officer | Buy(P) | 4K | $4.00 | $15K |
| May 26, 2021 | Payne Joseph E | Director | Buy(P) | 7K | $4.50 | $31K |
| May 25, 2021 | Payne Joseph E | Director | Buy(P) | 11K | $3.85 | $41K |
| May 14, 2021 | Ammer Richard | Director | Grant(A) | 15K | — | $0 |
| May 14, 2021 | Baker David Charles | Chief Executive Officer, Director | Grant(A) | 100K | — | $0 |
| May 14, 2021 | Toren Penny | SVP, Regul Affairs & Prog Mgmt | Grant(A) | 25K | — | $0 |
| May 14, 2021 | Kelly Leanne M. | Chief Financial Officer | Grant(A) | 70K | — | $0 |
| May 14, 2021 | Levi Ofir | Director | Grant(A) | 15K | — | $0 |
| May 14, 2021 | Levi Ofir | Director | Grant(A) | 30K | — | $0 |
| May 14, 2021 | Ammer Richard | Director | Grant(A) | 10K | — | $0 |
| May 14, 2021 | Payne Joseph E | Director | Grant(A) | 14K | — | $0 |
| May 14, 2021 | Payne Joseph E | Director | Grant(A) | 15K | — | $0 |
| Feb 12, 2021 | Baker David Charles | Chief Executive Officer, Director | Buy(P) | 1K | $8.00 | $8K |
| Feb 12, 2021 | Baker David Charles | Chief Executive Officer, Director | Other(J) | 8K | $6.40 | $50K |
| Feb 12, 2021 | Thorell Marella | Director | Grant(A) | 15K | — | $0 |
| Feb 12, 2021 | SALMON Pharma GmbH | 10% Owner | Other(J) | 47K | $6.40 | $301K |
| Feb 12, 2021 | Ammer Richard | Director | Other(J) | 47K | $6.40 | $301K |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: Vallon Pharmaceuticals, Inc., SEC CIK 0001824293. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under VLON and shows every filing by that issuer (also filed as GRI).
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-14. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for VLON